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Abstract
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Considerable progress has been made during the past twenty years towards elucidating the role of
peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in skin cancer. In 1999, the original
notion that PPARβ/δ was involved with epithelial cell function was postulated based on a
correlation between PPARβ/δ expression and the induction of mRNAs encoding proteins that
mediate terminal differentiation in keratinocytes. Subsequent studies definitively revealed that
PPARβ/δ could induce terminal differentiation and inhibit proliferation of keratinocytes.
Molecular mechanisms have since been discovered to explain how this nuclear receptor can be
targeted for preventing and treating skin cancer. This includes the regulation of terminal
differentiation, mitotic signaling, endoplasmic reticulum stress, and cellular senescence.
Interestingly, the effects of activating PPARβ/δ can preferentially target keratinocytes with genetic
mutations associated with skin cancer. This review provides the history and current understanding
of how PPARβ/δ can be targeted for both non-melanoma skin cancer and melanoma, and
postulates how future approaches that modulate PPARβ/δ signaling may be developed for the
prevention and treatment of these diseases.
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INTRODUCTION
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Peroxisome proliferator-activated receptor-α (PPARα) was the first PPAR identified in
19901 and later confirmed to be the key ligand-activated transcription factor that mediates
the pleiotropic effects induced by PPARα including serum lipid lowering and rodent-specific
hepatocarcinogenesis.2–7 Two more PPAR isoforms were discovered shortly thereafter and
termed PPARβ/δ (also known as PPARδ or PPARβ), and PPARγ.8,9 Initially, the regulation
of ligand-activated transcription factors including nuclear receptors such as PPARβ/δ was
described as a static mechanism (Fig. 1). This mechanism was thought to be initiated by
ligand binding to PPARβ/δ complexed with proteins that caused a conformational change in
PPARβ/δ. (reviewed in10) This conformational change allowed for dissociation of corepressor proteins that have histone deacetylase activity and recruitment of co-activator
proteins that have histone acetyltransferase activity, scaffolding proteins, and RNA
polymerase. The ligand bound, activated PPARβ/δ complex could then regulate expression
of target genes that was dependent on PPARβ/δ-specific response elements in the DNA
regulatory region of genes, usually upstream of transcription start sites. However, it is now
known that this static mechanism of nuclear receptor-mediated regulation of transcription,
such as that by PPARβ/δ, is actually dynamic in nature (Fig. 1) and constitutively occurring
in cells due to the presence of endogenous and exogenous ligands that bind to and modulate
PPARβ/δ activity (reviewed in10). This has been shown in many cell types including
keratinocytes by studies showing that PPARβ/δ is localized in the nucleus,and can be coimmunoprecipitated with PPARβ/δ and its heterodimerization partner retinoic acid X
receptor.11 In other words, the presence of endogenous ligands allows for PPARβ/δ to bind
to and modulate activity/expression of target genes in chromatin that becomes available by
the activities of other regulatory proteins in the nucleus.10 This is supported by studies
showing in the absence of PPARβ/δ in keratinocytes, expression of PPARβ/δ target genes is
markedly increased and decreased without treating the cells with exogenous ligands.10 Thus,
PPARβ/δ is able to regulate homeostasis based on the daily changes in the intracellular flux
of endogenous ligands, levels of expression of the receptor, and activities of chromatin
remodeling proteins that occurs in response to fasting and feeding, as well as exposure to
different physiological conditions or environmental factors.
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Since their discovery, the role of PPARs in cellular physiology has emerged extensively due
in large part to technological advances such as the generation of highly specific and unique
agonists and antagonists, transgenic animal and cell-based models, genome editing
facilitated by CRISPR/Cas9 models, and other molecular biology and biochemical models
developed in the past 20–30 years. It is well accepted that PPARα is a central regulator of
fatty acid catabolism, but also has other roles in normal homeostasis and in rodent-specific
hepatocarcinogenesis. (reviewed in12–15) By contrast, PPARγ is one of a number of
transcription factors that modulates adipogenesis, and has also been shown to have good
potential of targeting for cancer chemoprevention and chemotherapy15,16. Whereas the role
of PPARα, PPARγ, and PPARβ/δ in normal physiology is also clear, how PPARβ/δ
modulates cancer remains less certain in most instances due to contradictory studies.
(reviewed in15,17–23) However, the functional roles of PPARβ/δ in skin function and cancer
have been elucidated and the findings are less contentious (Table 1).
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PPARβ/δ-DEPENDENT REGULATION OF TERMINAL DIFFERENTIATION

AND PROLIFERATION OF KERATINOCYTES
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The first observation made suggesting that PPARβ/δ was involved in skin homeostasis was
the correlation between increased expression of the mRNAs encoding this nuclear receptor
and several proteins involved in squamous differentiation (e.g. transglutaminase I (TGI),
small proline rich proteins (SPR; also known as CORNIFIN) in normal human keratinocytes
in response to phorbol ester.24 Increased expression of Pparb/d mRNA was also noted in
CD-1 mouse skin following treatment with phorbol ester as compared to control.24
Considerable interest was generated by these results. Subsequent studies with a Pparb/d-null
mouse model more definitively determined whether PPARβ/δ was required to mediate these
effects. Surprisingly, while topical administration of phorbol ester markedly increased
expression of PPARβ/δ that was associated with increased expression of TG-1 and SPRs,
these changes were also observed in similarly treated Pparb/d-null mouse skin.25 This
suggested that PPARβ/δ was not required for phorbol ester-induced terminal differentiation
in skin. However, subsequent studies reported that treatment of both mouse and human
keratinocytes with the PPARβ/δ ligands GW501516 or L16504126 caused an increase in the
expression of proteins that mediate terminal differentiation and promote improved barrier
function.27,28 That ligand activation of PPARβ/δ promotes terminal differentiation was
definitely proven by demonstrating that the increase in expression of genes required for
inducing terminal differentiation by another PPARβ/δ ligand GW0742 and the associated
increased in cornified cells were only observed in wild-type mice but not in similarly treated
Pparb/d-null mouse skin and keratinocytes.29 Thus, one mechanism by which PPARβ/δ can
regulate skin homeostasis is through promoting terminal differentiation (Fig. 2A). This is of
interest because ligand activation of PPARβ/δ also induces terminal differentiation in many
other cell types. (reviewed in21,23,30)
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Given that ligand activation of PPARβ/δ promotes terminal differentiation in skin, and the
induction of terminal differentiation is associated with a concomitant inhibition of cell
proliferation,31,32 it is not surprising that early studies also revealed that PPARβ/δ attenuates
keratinocyte proliferation. This was first demonstrated with in vivo models where topical
application of phorbol ester caused exacerbated epidermal proliferation in Pparb/d-deficient
mouse skin as compared to controls.25,33 Moreover, expression of proliferating cellular
nuclear antigen (PCNA) was also higher in Pparb/d-null mouse skin as compared to wildtype mouse skin.34 These observations were extended by studies showing that ligand
activation of PPARβ/δ with GW0742 or L165041 indeed inhibits keratinocyte proliferation
in both in vitro and in vivo models. It is important to note that these effects were found in
three different Pparb/d-deficient mouse models, mouse primary keratinocytes, and human
and mouse cell lines,29,35–39 thus providing strong independent evidence of reproducibility.
The physiological role of PPARβ/δ in promoting terminal differentiation and inhibiting
keratinocyte proliferation made it a promising target for skin cancer chemoprevention and/or
chemotherapy.
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PPARβ/δ AND KERATINOCYTE PROGRAMMED CELL DEATH
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In contrast to the well-established roles for PPARβ/δ in regulating keratinocyte and
differentiation and proliferation, the role of PPARβ/δ in keratinocyte programmed cell death
is not as clear. The continual induction of terminal differentiation of basal keratinocytes into
cornified keratinocytes (envelopes) is known to be associated with a form of programmed
cell death, leading to the formation of the anucleated keratinocytes of the stratum corneum.
While the differentiation process shares some similarities with apoptosis (another form of
programmed cell death), it is important to note that the type of programmed cell death
signaling in differentiating keratinocytes is highly specialized to the cornification process
and differs substantially from apoptosis.40–42 For example, differentiating keratinocytes is
mediated in part by caspase 14, rather than classical caspase 3, 6 or 7.41 It is thus surprising
when others suggested that ligand activation of PPARβ/δ with L165041 caused downregulated expression of phosphatase and tensin homologue deleted on chromosome ten
(PTEN) and upregulated expression of 3-phosphoinositide-dependent kinase-1 (PDPK1) and
integrin-linked kinase-1 (ILK1), that collectively caused an increase in the phosphorylation
of protein kinase B (AKT1) and markedly inhibited apoptosis in keratinocytes.43 Since these
effects were observed in primary keratinocytes from wild-type mice but not in primary
keratinocytes from Pparb/d-null mice, this implied that these effects were mediated by
PPARβ/δ; but they are contradictory to the known unique form of programmed cell death in
keratinocytes.40–42 Additionally, the hypothetical pathway that ligand activation of PPARβ/δ
promotes anti-apoptotic signaling in keratinocytes through the proposed PTEN/PDPK1/
ILK1/AKT1 pathway is not supported by data showing that ligand activation of PPARβ/δ
with GW0742 in human N/TERT-1 keratinocytes increased expression of the known
PPARβ/δ target gene adipose differentiation-related protein (ADRP) but caused no change
in the expression of PTEN, PDPK1, ILK1 or phosphorylation of AKT1 as compared to
controls.38 Importantly, these analyses included temporal examination over a twenty-four
hour period.38 In the same studies, ligand activation of PPARβ/δ with GW0742 in mouse
primary keratinocytes also caused a marked increase in the expression of Adrp mRNA but
no changes in the expression of PTEN, ILK1, PDPK1, or phosphorylation of AKT1 as
compared to controls were noted.38 Additionally, changes in the expression of PTEN, ILK1
or PDPK1 are not observed following treatment with GW0742, whereas numerous PPARβ/δ
target genes are induced by GW0742 in wild-type but not Pparb/d-null keratinocytes.10 One
likely explanation for the differences between these two studies is that the primary
keratinocytes used by Di-Poi and colleagues did not exhibit the morphology of primary
keratinocytes44 and the constitutive expression of keratin 6 (K6), a standard marker of
hyperproliferation typically observed in primary keratinocytes was lacking,45 whereas
expression of this marker was present in the cells used in the latter studies.29 Thus, the cells
used by Di-Poi and colleagues that resembled keratinocytes do not appear to be
keratinocytes and this may explain the observed disparity between studies. Other studies also
do not support the hypothesis that ligand activation of PPARβ/δ down-regulates expression
of PTEN and upregulates expression of PDPK1 and ILK1, that collectively caused an
increase in the phosphorylation of AKT1 and inhibition of keratinocyte apoptosis as
suggested by others.43 For example, ligand activation of PPARβ/δ in human HaCaT cells
caused no change in AKT1 phosphorylation, and while no change in apoptosis was observed
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in HaCaT cells following ligand activation of PPARβ/δ at relatively low concentration of the
PPARβ/δ ligand GW0742, a relatively higher concentration of this PPARβ/δ ligand caused
an increase in early apoptosis in human HaCaT keratinocytes compared to controls.37 Overexpression and/or ligand activation of PPARβ/δ with GW0742 did not have any influence on
staurosporine- or ultraviolet (UV) light-induced apoptosis in human HaCaT cells as
compared to controls.46 Further, ligand activation of PPARβ/δ with GW501516 was
reported to increase expression of PTEN and inhibit phosphorylation of AKT1 in human
keratinocytes.47 Moreover, bioinformatic analyses of microarray and chromatin
immunoprecipitation sequencing (ChIP-seq) data revealed that ligand activation of PPARβ/δ
with GW0742 did not cause changes in PTEN/ILK1/PDPK1 expression or promoter
occupancy of PPARβ/δ on any of these genes in primary keratinocytes following ligand
activation of PPARβ/δ10 as suggested by a previous study.43 These studies are also
consistent with others experiments showing that ligand activation of PPARβ/δ with GW0742
or GW501516 in other cell types may actually increases PTEN expression and inhibit
phosphorylation of AKT1.48–50 Combined, the evidence that ligand activation of PPARβ/δ
inhibits apoptosis in keratinocytes via modulation of PTEN/ILK1/PDPK1/AKT1 is
inconsistent with many other studies, including those that have shown there is a unique form
of programmed cell death associated with keratinocyte differentiation that differs
substantially from apoptosis.40–42
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PPARβ/δ-DEPENDENT REGULATION OF NON-MELANOMA SKIN

CANCER: MULTIPLE REGULATORY MECHANISMS

Author Manuscript

The first evidence that PPARβ/δ could be targeted for non-melanoma skin cancer was the
observation that Pparb/d-null mice exhibited exacerbated chemically-induced skin
carcinogenesis using the classical two-stage chemical carcinogenesis bioassay51 (a single
topical application of dimethylbenzo[a]pyrene (DMBA) followed by multiple, weekly
topical application of a tumor promoter such as phorbol ester). This model was used for
many years to study non-melanoma skin cancer as it allows for dissecting the role of
initiation of DNA damage versus tumor promotion. The mechanisms underlying the cancer
chemopreventive effect modulated by PPARβ/δ have since been examined extensively in the
two-stage chemical carcinogenesis and related models.
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To determine if PPARβ/δ influenced DNA damage induced by DMBA, the effect of a
topical application on the expression of xenobiotic metabolizing enzymes required for
bioactivation of polycyclic aromatic hydrocarbons (PAH) to a mutagenic metabolite was
examined in wild-type and Pparb/d-null mice. Expression of cytochrome P450s (CYPs)
required for bioactivation of PAH was markedly reduced in Pparb/d-null mouse skin
following topical application of different PAHs as compared to similarly treated wild-type
mice.52 This study suggested that PPARβ/δ influenced the function of the aryl hydrocarbon
receptor (AHR). This difference was not due to altered expression of AHR, aryl hydrocarbon
receptor nuclear transporter, or heat shock protein 90.52 The relative ability of PAH to bind
to the AHR and the temporal translocation of the AHR into the nucleus also did not explain
the observed differences.52 However, occupancy of AHR on the Cyp1a1 enhancer region
was increased only in wild-type mouse skin but not in Pparb/d-null mouse skin by topical
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exposure to a PAH.52 The difference in the ability of the AHR to bind to the enhancing
element of the xenobiotic metabolizing enzyme CYP1A1 in Pparb/d-null mouse skin was
likely due to differences in the methylation pattern in this region that was mediated by a
mechanism that required PPARβ/δ.52 These results suggest that the absence of PPARβ/δ
expression modulates the epigenome. This was supported by functional analysis showing
that the number of DNA adducts following topical application of PAH was lower in Pparb/dnull mouse skin as compared to similarly treated wild-type mice.52 Since Pparb/d-null mice
exhibit enhanced non-melanoma skin cancer as compared to wild-type mice in the two-stage
chemical carcinogenesis bioassay, this suggests that PPARβ/δ likely regulates mechanisms
that modulate tumor promotion rather than initiation of DNA damage (Table 1).
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Since the absence of PPARβ/δ expression leads to enhanced non-melanoma skin cancer as
compared to wild-type mice in a two-stage chemical carcinogenesis bioassay,51 this
suggested that ligand activation of PPARβ/δ may inhibit chemically-induced skin cancer.
Indeed, multiple bioassays were performed revealing that activation of PPARβ/δ by topical
application of GW0742 can markedly inhibit the onset of skin tumor formation, and
decrease tumor multiplicity, and this effect is not found in similarly treated Pparb/d-null
mice.35,36,51,53 While it was of interest to determine whether ligand activation of PPARβ/δ
could inhibit malignant conversion of benign papillomas to squamous cell carcinomas
(SCC), the number of SCC observed in two-stage chemical carcinogenesis bioassays is low
when the genetic background of the mice is C57BL/6. An alternative strategy was used to
examine this hypothesis by determining the effect of ligand activation of PPARβ/δ using
mouse cell lines that exhibited phenotypes ranging from benign papillomas to SCC (308
cells, SP1 cells, and Pam212 cells). Ligand activation of PPARβ/δ with GW0742 inhibited
proliferation of all three cell lines as compared to controls,35,36 so these models did not
distinguish between effects that might be induced during early tumorigenesis versus those
that could be induced when a cell is more transformed in nature. These observations also
suggested that ligand activation of PPARβ/δ was likely effective for both cancer
chemoprevention and chemotherapy; consistent with past studies examining both of these
model systems.35,36,51,53
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The role of PPARβ/δ has also been examined using A431 cells, a human SCC cell line with
mutant EGFR and TP53 (the latter a common mutation observed in UV light-induced nonmelanoma skin cancer). The growth of ectopic xenografts derived from stable A431 cells
over-expressing PPARβ/δ was markedly inhibited and essentially negligible as compared to
controls A431 cells.54 Interestingly, ligand activation of PPARβ/δ with GW0742 did not
further influence this striking inhibition.54 These observations collectively provide support
that PPARβ/δ also inhibits human non-melanoma skin cancer associated with mutant TP53
and suggest that there are endogenous ligands for PPARβ/δ that may promote this phenotype
in cells that exhibit relatively high expression of PPARβ/δ such as keratinocytes.10,11
One of the first mechanisms examined to determine how ligand activation of PPARβ/δ
inhibits non-melanoma skin cancer was the induction of terminal differentiation (Fig. 2B,
Table 1). This is due to the fact that inducing terminal differentiation is known to cause
withdrawal from the cell cycle,31 a feature that has been targeted for impeding the growth of
cancer cells.55 Increased expression of gene products required for the induction of terminal
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differentiation has been observed in non-melanoma skin cancer models, both in vivo and in
vitro, in response to ligand activation of PPARβ/δ with GW0742 and the in vivo effects were
not found in similarly treated Pparb/d-null mice.35,36,53 These studies indicate that PPARβ/δ
may be used to prevent and treat non-melanoma skin cancer because activating this receptor
causes terminal differentiation of the solid tumors. Examination of target genes directly
regulated by PPARβ/δ using bioinformatic analyses of microarray and ChIP-seq data
revealed that none of the differentiation associated genes whose expression is increased by
PPARβ/δ activation are directly regulated by PPARβ/δ in mouse primary keratinocytes.10
Thus, further studies are still required to determine how ligand activation of PPARβ/δ
mediates the induction of terminal differentiation. This is most likely due to secondary
effects mediated by direct target genes regulated by PPARβ/δ based on the former data.10
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To begin to determine the mechanisms by which ligand activation of PPARβ/δ inhibits early
tumorigenesis, a series of studies were undertaken using models that utilized a Harvey
sarcoma ras (HRAS) retrovirus to introduce the key genetic mutation required for
keratinocytes to undergo malignant conversion in chemical carcinogenesis models.56 Ligand
activation of PPARβ/δ with GW0742 inhibited proliferation of HRAS-expressing primary
keratinocytes, but not in HRAS-expressing keratinocytes from Pparb/d-null mice (Table 1).
39 Proliferation of HRAS-expressing keratinocytes from Pparb/d-null mice was also
markedly increased as compared to HRAS-expressing keratinocytes from wild-type mice.
These observations are consistent with in vivo results showing that ligand activation of
PPARβ/δ inhibits cell proliferation in wild-type mice but not in similarly treated Pparb/dnull mice in two-stage chemical carcinogenesis bioassays.35,36,53 The PPARβ/δ-dependent
inhibition of HRAS-expressing keratinocyte proliferation was due to a block in the G2/M
phase of the cell cycle.39 Gene expression associated with promoting mitosis was markedly
repressed by ligand activation of PPARβ/δ with GW0742 in HRAS-expressing keratinocytes
from wild-type mice and this effect was not found in HRAS-expressing Pparb/d-null
keratinocytes.39 Results from these studies also showed that ligand activation of PPARβ/δ
targeted HRAS-expressing keratinocytes as compared to controls, and selectively caused
HRAS-expressing keratinocytes to undergo a block in the G2/M phase of the cell cycle. This
is interesting because the human SCC cell line A431 also exhibits a block in the G2/M phase
of the cell cycle in response to ligand activation of PPARβ/δ with GW0742,54 since these
cells are mutant for TP53 a common etiological factor in UV-induced non-melanoma skin
cancer. More detailed analyses of HRAS-expressing keratinocytes demonstrated that this
was mediated by E2F crosstalk with PPARβ/δ. Ligand activation of PPARβ/δ with GW0742
led to direct binding of p130/p107 with PPARβ/δ causing enhanced nuclear translocation
and increased promoter occupancy of p130/p107 on E2F target genes following resulting in
repression of gene products that promoted mitosis causing G2/M phase arrest in HRASexpressing keratinocytes.39 This is consistent with the known roles of p130/p107 in
repressing E2F target genes.57 These findings provide support for a combinatorial approach
to prevent non-melanoma skin cancer using mitosis inhibitors such as Paclitaxel with
specific PPARβ/δ ligands; an idea supported by synergistic effects observed in the former
studies.39
PPARβ/δ can also inhibit non-melanoma skin cancer by modulation of oncogene-induced
senescence (Fig. 2B, Table 1). HRAS-expressing primary keratinocytes typically exhibit
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calcium-induced differentiation and cell cycle arrest in vitro. Interestingly, HRASexpressing Pparb/d-null keratinocytes developed calcium-resistant foci that contained a high
percentage of cells that were undergoing replicative DNA synthesis, whereas HRASexpressing wild-type keratinocytes did not.58 Since HRAS can induce senescence to prevent
malignant transformation in vitro,59,60 it is of interest to note that HRAS-expressing wildtype keratinocytes cultured in high calcium medium exhibited a phenotype that resembled
senescent cells that was not found in HRAS-expressing Pparb/d-null keratinocytes.58 This
was consistent with a higher percentage of cells undergoing replicative DNA synthesis and a
lower percentage that were senescent in HRAS-expressing Pparb/d-null keratinocytes as
compared to wild-type keratinocytes. Ligand activation of PPARβ/δ with GW0742
decreased both the percentage of senescent cells and keratinocytes undergoing replicative
DNA synthesis in HRAS-expressing wild-type but not in Pparb/d-null keratinocytes
demonstrating that these effects required PPARβ/δ.58 Loss-of-function and gain-of-function
studies confirmed that PPARβ/δ promotes senescence in HRAS-expressing wild-type
keratinocytes by increasing phosphorylated mitogen-activated protein kinase kinase
(pMEK), pERK and HRAS GTP, as well as proteins involved in promoting senescence (p53,
p21, p27) as compared to HRAS-expressing Pparb/d-null keratinocytes.58 By contrast,
higher levels of pAKT1 were observed in HRAS-expressing Pparb/d-null keratinocytes
compared to HRAS-expressing wild-type keratinocytes. The mechanism underlying the
PPARβ/δ-dependent increase in expression of p53, p21 and p27 was mediated by repression
of pAKT caused by PPARβ/δ that led to enhanced forkhead box O (FOXO) activity and
decreased mouse double minute 2 homolog (MDM2).58 PPARβ/δ modulated expression of
both negative and positive protein regulators of HRAS (RASGAP120 and RASGRP1), and
follow-up studies showed that these changes contributed to the PPARβ/δ-dependent increase
in promotion of cellular senescence.58 Moreover, PPARβ/δ repressed expression of ILK1,
and increased pERK and decreased pAKT1 and mediated the increase in cellular senescence
by PPARβ/δ. In vivo tumors also exhibited higher expression of ILK1 and pAKT1 and the
percentage of dividing cells in tumors from Pparb/d-null mice as compared to controls was
consistent with the notion that pAKT1 inhibits FOXO and p27 expression. Through this
mechanism, PPARβ/δ promotes senescence and is anti-tumorigenic in a non-melanoma skin
cancer model by repressing ILK1 and pAKT1 signaling (Table 1).58
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Senescence can also be induced in non-melanoma skin cancer by PPARβ/δ-dependent
repression of HRAS-induced endoplasmic reticulum (ER) stress (Table 1), thus suppressing
carcinogenesis.61 HRAS expression caused enhanced ER-stress in Pparb/d-null
keratinocytes as compared to wild-type keratinocytes and this effect was mediated by ERstress activation of the unfolding response (UPR), in particular two of the three primary UPR
pathways: 1) ATF6, and 2) IRE1 but not the PERK pathway.61 These observations were
confirmed in both mouse and human models using loss-of-function, gain-of-function
models, and pharmacological inhibition. HRAS-dependent promotion of ER stress through
these pathways was mediated by increased pAKT1 activity in HRAS-expressing Pparb/dnull keratinocytes as compared to HRAS-expressing wild-type keratinocytes.61 Additional
studies showed that the differential phosphorylation of AKT1 was mediated by mammalian
target of rapamycin (mTOR), and that ER stress-induced UPR maintained higher pAKT1 in
part through a cell surface BiP-dependent mechanism.61 Interestingly, a transient increase in
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ER stress was sufficient to cause evasion of cellular senescence and malignant conversion in
an in vitro model of carcinogenesis. More importantly, ER stress also attenuated senescence
and promoted non-melanoma skin carcinogenesis an in vivo allograft model, and ER stress
was negatively correlated with cellular senescence in human benign colon lesions.61
Collectively, cellular senescence in non-melanoma skin cancer can be modulated by PPARβ/
δ-dependent regulatory mechanisms that involve regulation of pAKT, pERK, and ER stress,
and may be particularly important for cancer involving oncogenic RAS signaling.58,61
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Lastly, the original observation that Pparb/d-null mouse skin exhibits enhanced
inflammation following topical application of phorbol ester,25,51 suggests that PPARβ/δ may
also function to prevent non-melanoma skin cancer by inhibiting inflammation (Fig. 2B,
Table 1)). This is supported by other studies using different Pparb/d-deficient mice that also
exhibited exacerbated epidermal inflammation following topical treatment with phorbol
ester.33,34 While it is well established that PPARβ/δ has many anti-inflammatory activities,62
the precise mechanism by which PPARβ/δ inhibits inflammation in non-melanoma skin
cancer models requires further studies.
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The two-stage chemical carcinogenesis model of non-melanoma skin cancer provides a
useful model for dissecting the mechanisms of this disease and investigating approaches to
prevent and treat this disease. The UV-induced model of non-melanoma skin cancer more
closely reflects the etiology of non-melanoma skin cancer in humans. However, few studies
have been published to date that have examined the role of PPARβ/δ in modulating UVinduced non-melanoma skin cancer. In one study, UV exposure to skin caused an increase in
expression of Pparb/d mRNA.63 This is consistent with what is found in mouse skin/
keratinocytes exposed to phorbol ester and is likely to due to in part to increased activity of
AP1 since there is an AP1 response element in the mouse promoter for this gene.44
Surprisingly, the onset of tumor formation, the percentage of mice with tumors, and tumor
multiplicity were all inhibited in Pparb/d-null mice crossed with SKH1 hairless mice as
compared to wild-type controls.63 This is surprising because presumably the parent line of
Pparb/d-deficient mice used for these studies exhibited enhanced hyperplasia in response to
phorbol ester as compared to controls,33 consistent with what was observed with two other
lines of Pparb/d-null mice.25,34 This difference in tumorigenicity was attributed to PPARβ/δdependent regulation of oncogenic SRC.63 However, there are several weaknesses to this
study that preclude understanding whether PPARβ/δ-dependent regulation of SRC has a
critical role in UV-induced skin cancer.63 First, the effect of a topical application of a
PPARβ/δ ligand was not examined, so it is unclear from this study if ligand activation of
PPARβ/δ has any influence on UV-induced tumorigenicity as observed with the two-stage
chemical carcinogenesis model. SRC is also known to be a proto-oncogene and functions
more effectively in malignant conversion when there is an oncogenic mutation in the Y527
residue or in other genes that act on this phosphorylation site.64 Since the investigators did
not distinguish between the SRC proto-oncogene versus the oncogenic form of SRC, and
only measured SRC and SRC activities, it remains possible that the oncogenic properties of
SRC are unrelated to the observed phenotype. Additionally, while topical application of the
PPARβ/δ antagonist GSK0660 prevented the changes in SRC expression, and GSK0660 was
applied post-irradiation, this approach does not account for the sunscreen effect since it is
known that this compound strongly absorbs UV light and thus could prevent induction of
Mol Carcinog. Author manuscript; available in PMC 2020 September 01.
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any UV-induced effects. Lastly, the genetic background of the Pparb/d-null mice used for
these studies was mixed (Sv/129/C57BL) and it is well known that the genetic background
can markedly influence the outcome of skin cancer bioassays.65,66 In contrast to this study,
preliminary studies have shown that ligand activation of PPARβ/δ with GW0742 or sodium
oleate inhibits the onset of skin tumor formation, the incidence of tumor formation, and
tumor multiplicity in SKH1 hairless mice exposed to UVB, and these effects are not
observed in similarly treated SKH1 mice on a Pparb/d-null background.67 Since the latter
study applied topical PPARβ/δ ligands post-irradiation, the results from this study controlled
for the sunscreen effect and provide a better degree of clarity than the former study63 that
has multiple weaknesses. Additionally, inhibition of ectopic xenograft growth from A431
SCC cell line over-expressing PPARβ/δ provide further evidence that PPARβ/δ can inhibit
tumorigenesis of a human SCC cell line-derived xenografts that contain mutant TP53;54 a
signature mutation causally linked to UV-induced skin carcinogenesis. Thus, there remains a
need for more studies to determine the role of PPARβ/δ in UV-induced non-melanoma skin
cancer because results obtained from studies examining the effect of chemopreventive and
chemotherapeutic agents in two-chemical skin carcinogenesis models and xenograft studies
are typically similar to those observed in UV-induced skin cancer models.
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There are limited peer-reviewed publications focusing on the role of PPARβ/δ in melanoma.
The first study to examine the effect of ligand activation of PPARβ/δ with GW0742 in a
melanoma model showed concentration-dependent inhibition of cell proliferation by a
PPARβ/δ-specific ligand in a human melanoma cancer cell line as compared to controls.68
This inhibition of cell proliferation by ligand activation of PPARβ/δ with either GW0742 or
GW501516 was also found in both mouse and human melanoma cell lines and mediated by
repression of Wilm’s tumor suppressor 1 (WT1) that may in turn regulate expression of
NESTIN and ZYXIN.69 These findings are of interest to note because ligand activation of
PPARβ/δ with GW0742 and/or over-expression of PPARβ/δ inhibited growth of ectopic
xenografts derived from a human melanoma cell causing a block in cell proliferation at the
G2/M phase of the cell cycle and induction of apoptosis as compared to controls.70
Moreover, since the melanoma cell line used for two of these studies68,70 was UACC903,
which expresses mutant PTEN and an active AKT3, these results demonstrate that ligand
activation and/or over-expression of PPARβ/δ are capable of preventing the negative effects
of mutant PTEN and active AKT3, and possibly other mutations known to exist in this
melanoma cell line.71–73 Consistent with these studies, genetic ablation and pharmacological
inhibition of PPARβ/δ demonstrated that PPARβ/δ inhibited epithelial-mesenchymal
transition (EMT), migration, adhesion, and invasion of a mouse melanoma cell line, and that
PPARβ/δ prevented metastasis in a syngeneic mouse model of melanoma.74 By contrast, one
published study suggests that ligand activation of PPARβ/δ with GW501516 promotes
migration and invasion of a human melanoma cancer cell line.75 Combined, there is a
stronger weight of evidence that targeting PPARβ/δ for melanoma chemoprevention and
progression is a promising molecular target, although further studies are needed in more
melanoma models to increase the preclinical evidence to support this hypothesis.
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The role of PPARβ/δ in some cancer remains controversial due to conflicting reports with
some suggesting that PPARβ/δ promotes carcinogenesis and others suggesting that PPARβ/
δ inhibits carcinogenesis. (reviewed in15,20–22,30,76) By contrast, the role of PPARβ/δ in skin
cancer is clearer. There is strong evidence from multiple laboratories using a variety of
models showing that PPARβ/δ promotes terminal differentiation of both mouse and human
cells and this is associated with a concomitant inhibition of proliferation by inducing a block
at the G2/M phase of the cell cycle in response to ligand activation of PPARβ/δ. There is
also strong evidence that PPARβ/δ inhibits inflammatory responses in skin and related
models. Results from chemical carcinogen models and a xenograft model demonstrate that
PPARβ/δ inhibits non-melanoma skin cancer by inducing differentiation, inhibiting
proliferation and preventing inflammation (Fig. 2B, Table 1). At the molecular level, there
are several mechanisms that have been delineated that include crosstalk with E2F signaling
causing increased shuttling of PPARβ/δ with p130/p107 into the nucleus causing repression
of E2F target genes that collectively inhibit mitosis and cause a block at the G2/M phase of
the cell cycle. There are also at least two mechanisms by which PPARβ/δ promotes
oncogene-induced senescence. The first involves regulation of pAKT and pERK and the
other converges on the ER stress response that is also influenced by pAKT signaling.
Combined, these mechanisms explain at least in part how targeting PPARβ/δ can be used for
the prevention and treatment of non-melanoma skin cancer (Fig. 2B, Table 1).
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While the two-stage chemical carcinogenesis skin cancer bioassay provides an invaluable
tool to dissect out effects mediated by initiation and promotion of tumorigenesis, the primary
causal factor of non-melanoma skin cancer in humans is exposure to UV light. However,
whereas the two-stage chemical carcinogenesis model causes non-melanoma carcinogenesis
through mechanisms that are different than those elicited by exposure to UV light (e.g.
HRAS mutations versus TP53 mutations as initiating events), the effects of most, if not all,
chemopreventive agents are typically effective in both models as they likely act on molecular
pathways downstream from the initial DNA damage. Thus, while there remains a need for
more studies to study the role of PPARβ/δ in UV-induced non-melanoma skin cancer
models, it is more likely that activation of PPARβ/δ in UV-induced non-melanoma skin
cancer will also prove to be effective as a chemopreventive or chemotherapeutic approach
for this disease. This is supported by a study showing growth inhibition of ectopic
xenografts from A431 SCC cells with a mutant TP53 gene by over-expression of PPARβ/δ.
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The role of PPARβ/δ in melanoma is only beginning to emerge. The consensus from the
majority of studies performed to date indicate that ligand activation of PPARβ/δ may be
suitable for targeting for melanoma chemoprevention or chemotherapy, but further studies
are needed in models that better reflect the human disease (genetically modified animal
models).
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Figure 1.
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Modulation of cellular signaling by PPARβ/δ. PPARβ/δ dynamically binds with endogenous
and exogenous ligands, antagonists, and repressive ligands forming complexes with retinoic
acid X receptor (RXR) causing recruitment of co-activators with histone acetyl transferase
activities, histone de-acetylase activities, scaffolding proteins, and/or RNA polymerase
leading to increased or decreased expression of target genes. Target gene expression in turn
modulates cellular homeostasis. This dynamic regulation occurs constitutively due to the
presence of endogenous compounds that can bind to PPARβ/δ and modulate its
transcriptional activity and is particularly high in epithelial cells such as keratinocytes or
colonic epithelium.10,11 Moreover, the binding of PPARβ/δ to response elements in
chromatin is often accompanied by co-recruitment of other transcription factors such as
ATF4 that in turn modulate PPARβ/δ target gene expression.10 (A; upper panel) Typical
endogenous and exogenous PPARβ/δ ligands dynamically cause increased and decreased
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expression of target genes containing response elements usually near the transcription start
site through the mechanisms described above. (B; second panel below top) PPARβ/δ
antagonists dynamically compete with endogenous and exogenous ligands and can prevent
increased or decreased expression of target genes by outcompeting ligand binding and
preventing the ligand activated complex from modulating transcription.77 (C; third panel
below top) Selective, repressive ligands (also referred to as ‘inverse agonists”) selectively
recruit co-repressors and cause down-regulation of PPARβ/δ target genes by preventing
ligands from increasing expression due to the formation of this repressive complex. This
type of compound has not been examined in a skin cancer model to date (D; bottom panel)
PPARβ/δ can also interact with other proteins such as the p65 subunit of the NF-kB complex
and in turn down-regulate inflammatory signaling by decreasing NF-kB-dependent gene
expression.
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Figure 2.
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PPARβ/δ-dependent regulation of non-melanoma skin cancer. (A) Expression of PPARβ/δ is
high in keratinocytes,11 and is likely chronically activated by the presence of different
endogenous ligands.10 Ligand activation of PPARβ/δ promotes terminal differentiation by
increasing expression of keratins, small proline-rich proteins (SPRs), transglutaminase-I
(TG), etc. and inhibits keratinocyte proliferation by doing so. This signaling likely helps to
maintain skin homeostasis and a mechanism to help protect cells from exogenous agents
such as chemical carcinogens and UV light. (B) Ligand activation of PPARβ/δ inhibits nonmelanoma skin cancer by inducing terminal differentiation, inhibiting cell proliferation,
inhibiting inflammation, and can also promote senescence through two mechanisms: 1)
crosstalk with E2F signaling whereby PPARβ/δ shuttles p130/p107 across the nuclear
membrane causing repression of E2F target genes and a block at the G2/M phase of the cell
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cycle, and 2) PPARβ/δ-dependent repression of oncogene-induced ER stress that promotes
senescence.
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Summary of effects mediated by PPARβ/δ in skin and skin cancer models
Effect

Reference(s)

Author Manuscript

Activation of PPARβ/δ causes increased terminal differentiation

24,27–29

Activation of PPARβ/δ causes inhibition of proliferation

25,29,33–39

PPARβ/δ modulates bioactivation of chemical carcinogens

52

Ligand activation of PPARβ/δ inhibits non-melanoma skin cancer

35,36,51,53,54

Inhibition of non-melanoma skin cancer by PPARβ/δ mediated by enhanced terminal differentiation

35,36,53

Inhibition of non-melanoma skin cancer by PPARβ/δ mediated by a block in the G2/M phase of cell cycle

39,54

Inhibition of non-melanoma skin cancer by PPARβ/δ mediated by enhanced senescence

58

Inhibition of non-melanoma skin cancer by PPARβ/δ mediated by inhibition of ER stress

61

Inhibition of non-melanoma skin cancer by PPARβ/δ influenced by inhibition of pro-inflammatory signaling

25,33,34,51

Ligand activation of PPARβ/δ inhibits melanoma

70,71,74,75
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